Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks 

Page 4 of 10

7. Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders In Q1 2025: 60

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s shares have lost 15.7% year-to-date. Novo Nordisk A/S (NYSE:NVO) has struggled primarily due to investor fears about Eli Lilly overtaking the firm in the weight loss drug market. Other news, such as a surprise departure of the firm’s CEO hasn’t helped the stock pare back its losses either. Novo Nordisk A/S (NYSE:NVO)’s stock lost 6% in March after its CagriSema weight loss drug fell short of the firm’s estimates. While it had expected the drug to help users lose 25% of their body weight, the trials led to a 15.7% weight reduction. Cramer commented on activist investor Parvus taking a stake in the company:

[On activist fund Parvus building a stake in the company] How could they be so far behind? You know they were first, they were first mover. And then Lilly came along, Lilly by the way, still a great stock. But maybe this is going to shake up Novo.

“How about better science?. . . Because they fell behind Lilly!

In his previous comments about Novo Nordisk A/S (NYSE:NVO), Cramer commented on the firm in the context of Eli Lilly:

“Okay, Eli Lilly. We bought some just the other day for the Charitable Trust. Why did we do that? Because it’s down very big and yet it’s been beating Novo Nordisk over and over and over again. So I just think this is a decent level to start a position if you don’t have any.”

Page 4 of 10